They got that backwards. In the clinical trial of iADT for metastatic patients (SWOG 9346), Hussain reported on a subgroup analysis that men with more extensive disease did equally well with intermittent or continuous ADT (hazard ratio 1.0). Men with less extensive metastases did better with continuous ADT (hazard ratio 1.20), but the difference was not statistically significant.
www.nejm.org/doi/full/10.1056/NEJMoa1212299